Product
Olaparib + Durvalumab + UV1
1 clinical trial
1 indication
Indication
Ovarian CancerClinical trial
A Randomized Clinical Trial Investigating Olaparib, Durvalumab (MEDI4736) and UV1 as Maintenance Therapy in BRCAwt Patients With Recurrent Ovarian CancerStatus: Recruiting, Estimated PCD: 2024-12-15